Radioimmunotherapy phase I dose-escalation studies in prostate cancer using 177Lu-J591 [MLN 591RL] antibody: Dose fractionation regimen

Trial Profile

Radioimmunotherapy phase I dose-escalation studies in prostate cancer using 177Lu-J591 [MLN 591RL] antibody: Dose fractionation regimen

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs ATL 101 Telix Pharmaceuticals (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 01 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top